Arterial infusion chemotherapy concurrent with radiation therapy followed by systemic gemcitabine and cisplatin therapy for unresectable biliary tract cancer patients; A phase2 study

Arterial infusion chemotherapy concurrent with radiation therapy followed by systemic gemcitabine and cisplatin therapy for unresectable biliary tract cancer patients; A phase2 study - A phase2 study of AI+RT followed by systemic GEM+CDDP therapy for unresectable biliary tract cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023906

Enrollment

Registered

2016-09-02

Start date

2015-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer

Interventions

Arterial infusion chemotherapy and radiation therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: It has been confirmed to be biliary tract cancer by pathological examination.

Exclusion criteria

Exclusion criteria: Resectable biliary tract cancer

Design outcomes

Primary

Measure	Time frame
Response rate, disease control rate, adverse events rate	—

Secondary

Measure	Time frame
Median survival, protocol treatment completion rate, CA19-9 response rate, progression-free survival, distant metastasis-free survival, 1-year survival rate, 2-year survival rate	—

Countries

Japan

Contacts

Public ContactTakuma Goto

Asahikawa medical university Department of Medicine Division of Gastroenterology and Hematology / Oncology

t-gotti@asahikawa-med.ac.jp0166-68-2462

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026